Dr. Garassino Discusses Promising Findings With Osimertinib for Patients With NSCLC and Brain Mets

Marina Chiara Garassino, MD
Published: Tuesday, Jun 06, 2017



Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.


Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x